Advertisement

Why Do Physicians Order NSCLC Biomarker Tests, and Who Gets Appropriate Targeted Therapy?

Jul 25, 2024

REFERENCES & ADDITIONAL READING

Levant A, De Richter P. Reasons for biomarker testing in NSCLC: An analysis of reasoning between 2021-2023 in early- vs. late-stage patients. J Clin Oncol. 42, 2024 (suppl 16; abstr e15175). doi:10.1200/JCO.2024.42.16_suppl.e15175

Videna V, et al. Biomarker testing and targeted therapy use among patients with non-small cell lung cancer in the United States: An analysis using a physician notes real-world database. J Clin Oncol. 42, 2024 (suppl 16; abstr 11175). doi:10.1200/JCO.2024.42.16_suppl.11175

ABOUT THE EXPERTS

Ayse Levent, MSc

Senior Vice President
Global Therapy Monitors
Ipsos

Vernon Videna, Pharm D, RPh

Senior Medical Writer
Amplify Health

Pieter De Richter

Regional Syndicated Service Leader
APAC & MENA Healthcare
Head of APAC Syndicated Real World Evidence & Chief Strategy Officer
Molecular Diagnostics
Ipsos

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement